|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
|
|
|
|||||||||
|
|||||||||||
|
J Am Coll Cardiol, 2005; 46:1225-1228, doi:10.1016/j.jacc.2005.07.006 © 2005 by the American College of Cardiology Foundation |
Donald W. Reynolds Cardiovascular Clinical Research Center, Department of Medicine, Brigham and Women’s Hospital, and Harvard Medical School, Boston, Massachusetts.
Manuscript received February 4, 2005; accepted February 16, 2005.
* Reprint requests and correspondence: Dr. Peter Libby, Brigham and Women’s Hospital, 77 Avenue Louis Pasteur, NRB 741, Boston, Massachusetts 02115. (Email: plibby{at}rics.bwh.harvard.edu).
Despite meaningful progress in the identification of risk factors and the development of highly effective clinical tools, deaths from cardiovascular disease continue to increase worldwide. Sparked by an obesity epidemic, the metabolic syndrome and the rising incidence of type 2 diabetes have led to an upsurge of cardiovascular risk. Although pharmacologic treatments with the statin class of drugs have reduced cholesterol levels and lowered mortality rates, several large controlled clinical trials, including the Scandinavian Simvastatin Survival Study, the Cholesterol and Recurrent Events trial, the Air Force/Texas Coronary Atherosclerosis Prevention studies, and Long-term Intervention with Pravastatin in Ischemic Disease study, have indicated that cardiovascular events continue to occur in two thirds of all patients. Follow-up studies, such as the Heart Protection Study and the Pravastatin or Atorvastatin Evaluation and Infection Therapy/Thrombolysis In Myocardial Infarction-22 trials, reinforced these earlier results. Although therapy with gemfibrozil, a fibric acid derivative, showed reduced occurrence of cardiovascular events in the Helsinki Heart Study and the Veterans Affairs HDL Intervention Trial, results of other studies, e.g., the Bezafibrate Intervention Program and the Diabetes Atherosclerosis Intervention study, showed less encouraging results. Although lifestyle modifications, such as improved diet and increased exercise levels, benefit general health and the metabolic syndrome and insulin resistance in particular, most people continue to resist changes in their daily routines. Thus, physicians must continue to educate their patients regarding an optimal balance of drug therapy and personal behavior.
| |||||
This article has been cited by other articles:
|
|
 |
|
  D. Steinberg, C. K. Glass, and J. L. Witztum Evidence Mandating Earlier and More Aggressive Treatment of Hypercholesterolemia Circulation, August 5, 2008; 118(6): 672 - 677. [Full Text] [PDF]
|
|
|
|
 |
|
 E. Thorp, D. Cui, D. M. Schrijvers, G. Kuriakose, and I. Tabas Mertk Receptor Mutation Reduces Efferocytosis Efficiency and Promotes Apoptotic Cell Accumulation and Plaque Necrosis in Atherosclerotic Lesions of Apoe-/- Mice Arterioscler. Thromb. Vasc. Biol., August 1, 2008; 28(8): 1421 - 1428. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Koenig Treating Residual Cardiovascular Risk: Will Lipoprotein-Associated Phospholipase A2 Inhibition Live Up to Its Promise? J. Am. Coll. Cardiol., April 29, 2008; 51(17): 1642 - 1644. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Barton, R. Minotti, and E. Haas Inflammation and Atherosclerosis Circ. Res., October 12, 2007; 101(8): 750 - 751. [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Nissen, J.-C. Tardif, S. J. Nicholls, J. H. Revkin, C. L. Shear, W. T. Duggan, W. Ruzyllo, W. B. Bachinsky, G. P. Lasala, E. M. Tuzcu, et al. Effect of Torcetrapib on the Progression of Coronary Atherosclerosis N. Engl. J. Med., March 29, 2007; 356(13): 1304 - 1316. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Nissen, S. J. Nicholls, K. Wolski, D. C. Howey, E. McErlean, M.-D. Wang, E. V. Gomez, and J. M. Russo Effects of a Potent and Selective PPAR-{alpha} Agonist in Patients With Atherogenic Dyslipidemia or Hypercholesterolemia: Two Randomized Controlled Trials JAMA, March 28, 2007; 297(12): 1362 - 1373. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Cubbon, S. B. Wheatcroft, P. J. Grant, C. P. Gale, J. H. Barth, R. J. Sapsford, R. Ajjan, M. T. Kearney, A. S. Hall, and on behalf of the EMMACE (Evaluation of Methods and Temporal trends in mortality of patients with diabetes mellitus suffering acute myocardial infarction: a comparison of over 3000 patients between 1995 and 2003 Eur. Heart J., March 1, 2007; 28(5): 540 - 545. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Libby Fat Fuels the Flame: Triglyceride-Rich Lipoproteins and Arterial Inflammation Circ. Res., February 16, 2007; 100(3): 299 - 301. [Full Text] [PDF]
|
|
|
|
 |
|
 K. B. Keller and L. Lemberg Secondary prevention of coronary artery disease in elderly persons: a treatise on a report by the american heart association. Am. J. Crit. Care., September 1, 2006; 15(5): 514 - 518. [Full Text] [PDF]
|
|
|
|
|
|
J.-C. Tardif, T. Heinonen, D. Orloff, and P. Libby Vascular Biomarkers and Surrogates in Cardiovascular Disease Circulation, June 27, 2006; 113(25): 2936 - 2942. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Nissen, E. M. Tuzcu, H. B. Brewer, I. Sipahi, S. J. Nicholls, P. Ganz, P. Schoenhagen, D. D. Waters, C. J. Pepine, T. D. Crowe, et al. Effect of ACAT inhibition on the progression of coronary atherosclerosis. N. Engl. J. Med., March 23, 2006; 354(12): 1253 - 1263. [Abstract] [Full Text] [PDF]
|
|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
